Postoperative short-term use of the nonsteroidal anti-inflammatory drug flurbiprofen did not increase the anastomotic leakage rate in patients undergoing elective gastrointestinal surgery—a retrospective cohort study

Huang Nie1†, Yiming Hao2†, Xiangying Feng2, Lina Ma1, Yumei Ma1, Zhen Zhang1, Xi’an Han3, Jian zhong Zhang1, Ping Zhang2, Qingchuan Zhao2* and Hailong Dong1*

Abstract

Background: Flurbiprofen has been one of the most commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) in China and other Asian countries for perioperative multimodal analgesia in recent years, yet its association with anastomotic leakage in gastrointestinal anastomoses is unknown. The current study was designed to investigate whether short-term administration of flurbiprofen would increase the risk of anastomotic leakage in patients undergoing gastrointestinal surgery for cancer resection.

Methods: A total of 3653 patients (2487 (66.1%) men) undergoing elective operation for gastrointestinal cancer between 18 July 2017 and 30 Oct 2020 were included. The median age was 61 years (interquartile range 53–67 years). The exposure was the short-term postoperative use of flurbiprofen (defined as flurbiprofen treatment within the first week after surgery). The primary outcome was the frequency of clinical anastomotic leakage.

Results: Of 3653 patients with available data who were included in the final analysis, 2282 received flurbiprofen administration, and 1371 did not. Anastomotic leakage was not significantly increased among the patients receiving flurbiprofen compared with those who did not (1.62% v 1.46%; \(P=0.70\)). In-hospital mortality was comparable between the two groups (0.04% v 0.07%; \(P=0.72\)). After adjusted analysis, male sex (OR 3.51, 95% CI 1.80–6.85), ASA score of 3–4 (OR 2.69, 95% CI 1.62–4.48), and intraoperative infusion (OR 2.24, 95% CI 1.19–4.21) were identified as risk factors for anastomotic leakage.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Anastomotic leakage following gastrointestinal surgery is a potentially serious complication resulting in increased postoperative morbidity and mortality. The reported leakage rates are approximately 3% after colonic resections and 10% after rectal resections, with mortality rates of up to 32% (Guenaga et al. 2009; Choi et al. 2006). For gastric cancer patients undergoing gastrectomy, the leakage rate was reported to be 2.7–15% (Haga et al. 2011; Inokuchi et al. 2015).

In the past two decades, NSAIDs have been strongly recommended by the Enhanced Recovery After Surgery Society (Nygren et al. 2012; Mortensen et al. 2014) as important multimodal analgesic components for various surgeries; thus, the possible effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on the risk of anastomotic leakage has been increasingly studied. Retrospective studies have shown an association between anastomotic leakage and postoperative treatment with NSAIDs (Klein et al. 2012; Klein et al. 2009; Gorissen et al. 2012). Although animal studies have suggested that reduced collagen production and microthromboses resulting from cyclooxygenase inhibition might explain the adverse effects of NSAIDs, their anti-inflammatory effects may be beneficial after surgery. Controversy remains about whether and which type (nonselective or cyclooxygenase-2 selective) of NSAIDs are associated with anastomotic leakage (Jamjittrong et al. 2020).

Currently, the nonselective NSAID flurbiprofen is widely used during the early postoperative period in most hospitals in China and other Asian countries. However, no investigation has studied whether short-term administration of flurbiprofen increases the risk of anastomotic leakage after gastrointestinal surgery. To investigate the possible effect of postoperative flurbiprofen treatment on patients undergoing gastrointestinal surgery, we performed a study based on data from the “Real World Study of Enhanced Recovery After Surgery Program” of a tertiary teaching hospital, which included detailed information on perioperative treatment.

Materials and methods
Patients and study design
This study was based on data from the “Real World Study of Enhanced Recovery After Surgery Program” of a tertiary teaching hospital. We aimed to compare the risk of anastomotic leakage among patients receiving flurbiprofen, which is the most commonly used NSAID in our hospital, with those not receiving regular NSAID treatment. With the electronic recording systems, all treatments administered at our hospital were documented.

This retrospective cohort study enrolled consecutive patients from a tertiary hospital between 18 July 2017 and 30 Oct 2020. Patients were deemed eligible for inclusion if they were scheduled for elective gastrointestinal surgery for gastrointestinal cancer and received a primary anastomosis. The exclusion criteria were (1) patients receiving more than one type of NSAID; (2) patients receiving NSAIDs other than flurbiprofen; or (3) patients receiving flurbiprofen for more than 7 days after surgery. This study was approved by KY20202116-C-1 from Approval Form I E C of our hospital. The report was written in accordance with the STROBE Statement (Vandenbroucke et al. 2014). The study was reported in line with the STROCSS criteria (Agha et al. 2019).

Data collection and definition
Data pertaining to baseline demographics, medical interventions, and clinical outcomes were obtained prospectively and automatically saved in the database prior to analysis. The system we used for data collection and derivation was developed by Unimed Scientific, Inc. (Wu Xi, China). From the database, we retrieved information on demographic variables, alcohol and tobacco use, comorbidities (pre-existing diabetes mellitus, ischemic heart disease, respiratory system disease, or hypertension), procedure type, open or laparoscopic procedure, tumor T stage, intraoperative blood loss (mL) and transfusion (whether it occurred or not), and anastomotic leakage. We defined the relevant daily dose as at least 50 mg and maximal dose of 200 mg for flurbiprofen. Anastomotic leakage was defined as leakage detected symptomatically, radiologically, or during surgery (Matthiessen et al. 2007).

Statistical analysis
Data are shown as medians and interquartile ranges for continuous variables and frequencies and proportions for categorical variables. Between-group differences were assessed via a two-tailed Student’s t test (for parametric variables) or the Mann-Whitney U test (for nonparametric variables). Categorical variables were analyzed via the chi-square test, CMH-chi-square test, or Fisher’s exact test as appropriate. To identify possible risk factors for

Conclusions: Postoperative short-term use of flurbiprofen did not increase the risk of anastomotic leakage in gastrointestinal anastomoses.

Keywords: Nonsteroidal anti-inflammatory drugs, Flurbiprofen, Gastrointestinal surgery, Anastomotic leakage
anastomotic leakage, we planned to perform univariate logistic regression analyses on all variables with less than 10% missing data. These variables included NSAID use, intraoperative transfusion, colorectal section or gastrectomy, sex, age at time of operation, intraoperative blood loss, American Society of Anesthesiologists score, open or laparoscopic surgery, and tumor T stage. We included all variables with \( P < 0.2 \) in a multivariate logistic regression analysis, and we also performed stepwise regression analysis (method: backward, likelihood ratio). We presented the results as odds ratios (ORs) and 95% confidence intervals (CIs) and \( P \) values. Differences between independent proportions were calculated as absolute risk increases with confidence intervals and calculated according to the method in reference (Newcombe 1998). Statistical tests were interpreted at a two-sided significance level of 5%. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA).

Results

Study participants and data completeness

Based on the inclusion criteria, we retrieved data for 4128 patients with elective gastrointestinal cancer resection and primary anastomosis from our surgical database (Fig. 1). Of these, 198 patients were excluded for administration of NSAIDs other than flurbiprofen, 162 patients were excluded for two types of NSAID use, and 115 were excluded for more than 7 days of administration. After exclusion of these patients, 3653 remained for final analysis. In this group, 2282 (62%) patients received postoperative treatment with flurbiprofen, and 1371 (38%) did not receive NSAIDs. Of all the variables, tobacco use and alcohol had approximately 30% missing data, whereas others’ completeness was above 99%.

Patient demographic and clinical details

Table 1 presents the demographic variables and data completeness. The median age of the entire study population was 61 years (interquartile range 53–67 years), and 2487 (68.1%) were men. A total of 2054 patients underwent curative gastrectomy for gastric cancer, and 1599 underwent colorectal surgery for colorectal carcinoma. We found 1708 (47%) laparoscopic procedures. Overall, 57 patients had anastomotic leakage, and 2 (0.05%) died in the hospital. There were more female patients in the flurbiprofen group than in the control group. We observed more patients with ischemic heart disease in the flurbiprofen group. Patients who received flurbiprofen had more laparoscopic procedures and more colorectal surgeries. Less intraoperative blood loss was found, and intraoperative transfusion was less frequent in patients receiving flurbiprofen (Table 2).

Anastomotic leakage in relation to flurbiprofen use

In total, 57 (1.56%) patients had a symptomatic anastomotic leak. According to ISREC’s grading system (Kulu et al. 2013), 1 patient was graded A, 27 (47.4%) patients were graded B, and 29 (50.9%) patients were graded C. The leaks were diagnosed on postoperative day 4 at a
median (interquartile range 3–6 days). Anastomotic leakage occurred in 37 (1.62%) patients treated with flurbiprofen and in 20 (1.36%) controls. With regard to postoperative flurbiprofen treatment, no increased risk was found ($P=0.70$). To identify individual risk factors for anastomotic leakage, based on less than 10% missing data, we performed univariate logistic regression analyses (Table 3). Based on the $P<0.2$ limit, we included sex, intraoperative transfusion, ASA score, and tumor stage in the multivariate analysis (Table 4). The analysis showed a significantly increased risk of anastomotic leakage in males (odds ratio 3.51, (95% confidence interval 1.58 to 7.78); $P=0.002$) and in those with an ASA score higher than 2 (odds ratio 2.67, (95% confidence interval 1.45 to 4.92); $P=0.0016$). Additionally, we performed stepwise regression analysis (Table 5). Male sex (odds ratio 3.51 (95% confidence interval 1.80 to 6.85); $P=0.002$), ASA score higher than 2 (odds ratio 2.69 (95% confidence interval 1.62 to 4.48); $P=0.0014$) and intraoperative transfusion (odds ratio 2.24 (95% confidence interval 1.19 to 4.21); $P=0.0365$) were associated with an increased risk of anastomotic leakage.

### Discussion

To our knowledge, this was the first large retrospective study to investigate whether short-term administration of flurbiprofen increases the risk of anastomotic leakage after elective gastrointestinal surgery. Our results showed that postoperative administration of flurbiprofen within 1 week did not increase the anastomotic leakage rate in patients undergoing elective gastrointestinal surgery for carcinoma resection.

First, the strength of this study is the large number of patients included, ensuring high statistical power in the analyses. Second, unlike most retrospective studies that only covered colorectal surgery, our study focused on both upper and lower gastrointestinal tract surgery. Since NSAIDs are often used in analgesic regimens to spare opioids in such circumstances (McDaid et al. 2010; Zhang et al. 2011), our results are relevant to daily clinical practice. Moreover, patients’ NSAID exposure was completely and reliably recorded, thus minimizing the risk of misclassification. Finally, our study investigated the association of regularly used flurbiprofen (widely used in China and other countries) and anastomotic leakage (Zhang et al. 2011; Nishina et al. 2000; Sultan et al. 2009). To some extent, the result could alleviate the worries about using flurbiprofen for multimodal analgesia in this group of patients.

A limitation of this study is that it is not population-based, thereby allowing the possibility of selection bias. In addition, as a retrospective observational study, this report is vulnerable to bias and confounding. However, we adjusted the results by multivariate logistic regression, as is recommended to reduce confounding.

The association between NSAIDs and anastomotic leakage has been evaluated in many studies; however, the different types of NSAIDs and leak definitions make comparisons difficult. Although several retrospective studies have indicated an increased risk of leakage after NSAID treatment, a number of more recent

### Table 1 Population characteristics and data completeness

|                          | Total study populations ($n=3653$) | Missing data (%) |
|--------------------------|------------------------------------|------------------|
| **Age**                  | 61 (53–67)                         | 0                |
| **Sex**                  |                                    |                  |
| Male                     | 2487 (68.08%)                      | 0                |
| Female                   | 1166 (31.92%)                      | 0                |
| **BMI**                  | 23 (20.9–25.1)                     | 0.27             |
| **Tobacco use**          |                                    |                  |
| Non-smoker               | 1532 (60.58%)                      | 30.19            |
| Previous smoker          | 842 (33.02%)                       | 0                |
| Active smoker            | 176 (6.90%)                        | 0                |
| **Alcohol**              |                                    |                  |
| Non-drinker              | 1822 (71.65%)                      | 30.38            |
| Previous drinker         | 613 (24.10%)                       | 0                |
| Active drinker           | 108 (4.25%)                        | 0                |
| **Ischemic heart disease**| 129 (3.53%)                        | 0                |
| **Hypertension**         | 757 (20.72%)                       | 0                |
| **Diabetes**             | 338 (9.25%)                        | 0                |
| **Respiratory system disease**| 31 (0.85%)               | 0                |
| **ASA score**            |                                    |                  |
| 1                        | 66 (1.81%)                         | 0.05             |
| 2                        | 3160 (86.55%)                      | 0                |
| 3                        | 411 (11.26%)                       | 0                |
| 4                        | 14 (0.38%)                         | 0                |
| **Tumor stage (pTNM)**   |                                    |                  |
| 1                        | 947 (25.92%)                       | 0                |
| 2                        | 1138 (31.15%)                      | 0                |
| 3                        | 1541 (42.18%)                      | 0                |
| 4                        | 27 (0.75%)                         | 0                |
| **Procedure type**       |                                    |                  |
| Gastrectomy              | 2054 (56.22%)                      | 0                |
| Colorectomy              | 1599 (43.77%)                      | 0                |
| **Procedure approach**   |                                    |                  |
| Laparoscopic             | 1708 (46.76%)                      | 0                |
| Open                     | 1945 (53.24%)                      | 0                |
| **Intraoperative blood loss (ml)**| 100 (50–150) | 0.19            |
| Intraoperative transfusion| 249 (6.82%)                        | 0                |
| Operating duration       | 3 (2.42–3.83)                      | 0                |
| Anastomotic leakage      | 57 (1.56%)                         | 0                |
| In-hospital mortality    | 2 (0.05%)                          | 0                |
studies presented similar results as ours (Klein et al. 2009; Gorissen et al. 2012). In Washington State’s Surgical Care and Outcomes Assessment Program (SCOAP), data from colorectal and bariatric surgery indicated that any NSAID use within 24 h following surgery did not increase the risk of leakage. Saleb et al. investigated the effect of the nonselective agent ketorolac on anastomotic leakage and found no increase in risk after treatment (Saleh et al. 2014). In a Swedish retrospective multicenter cohort study, NSAID use after anterior resection for rectal cancer did not increase the risk of anastomotic leakage (Kverneng Hultberg et al. 2017). In the stepwise regression analysis, we identified risk factors for anastomotic leakage. Male sex and blood transfusion have been suggested to increase the risk of anastomotic leakage both in colorectal and gastric anastomosis (Iversen et al. 2008; Lipska et al. 2006; Alves et al. 2002; Golub et al. 1997; Mäkelä et al. 2003).

Table 2 Population characteristics and surgical factors according to NSAID use

|                  | Flurbiprofen (n=2282) | No NSAIDs (n=1371) | P value |
|------------------|-----------------------|--------------------|---------|
| Age              | 61 (53–67)            | 61 (54–68)         | 0.2759  |
| Sex, n (%)       |                       |                    |         |
| Male             | 1524 (66.78%)         | 963 (70.24%)       | 0.03    |
| Female           | 758 (33.22%)          | 408 (29.76%)       |         |
| BMI              | 23 (20.9–25)          | 23 (20.9–25.1)     | 0.7447  |
| Tobacco use      |                       |                    |         |
| Non-smoker       | 952 (60.33%)          | 580 (59.67%)       |         |
| Previous smoker  | 514 (22.57%)          | 328 (33.74%)       |         |
| Active smoker    | 112 (7.10%)           | 64 (6.58%)         |         |
| Alcohol          |                       |                    |         |
| Non-drinker      | 1123 (71.44%)         | 699 (71.99%)       | 0.7876  |
| Previous drinker | 386 (24.55 %)         | 227 (23.38%)       |         |
| Active drinker   | 63 (4.01%)            | 45 (4.63%)         |         |
| Ischemic heart disease | 93 (4.08%) | 36 (2.63%) | 0.0215 |
| Hypertension     | 481 (21.08%)          | 276 (20.13%)       | 0.4943  |
| Diabetes         | 213(9.93%)            | 125 (9.12%)        | 0.8269  |
| Respiratory system disease | 19 (0.83%) | 12 (0.88%) | 0.8917 |
| ASA score        |                       |                    | 0.7537  |
| 1                | 44 (1.93%)            | 22 (1.61%)         |         |
| 2                | 1964 (86.10%)         | 1196 (87.3%)       |         |
| 3                | 264 (11.57%)          | 147 (10.73%)       |         |
| 4                | 9 (0.39%)             | 5 (0.36%)          |         |
| Tumor stage      |                       |                    | 0.4766  |
| 1                | 574 (25.15%)          | 373 (27.21%)       |         |
| 2                | 717 (31.42%)          | 421 (30.71%)       |         |
| 3                | 972 (42.59%)          | 569 (41.50%)       |         |
| 4                | 19 (0.83%)            | 8 (0.58%)          |         |
| Procedure type   |                       |                    | <.0001  |
| Gastrectomy      | 1222 (53.55%)         | 832 (60.69%)       |         |
| Colectomy        | 1060 (46.45%)         | 539 (39.31%)       |         |
| Procedure approach |                    |                    | <.0001  |
| Laparoscopic     | 1256 (55.04%)         | 452 (33.09%)       |         |
| Open             | 1026 (44.96%)         | 919 (66.91%)       |         |
| Intraoperative blood loss (ml) | 100 (50–150) | 100 (50–200) | <.0001 |
| Intraoperative transfusion (yes) | 140 (6.13%) | 109 (7.95%) | 0.035 |
| Operating duration | 3 (2.42–3.83) | 3 (2.42–3.75) | 0.809 |
| Anastomotic leakage | 37 (1.62%) | 20 (1.46%) | 0.701 |
| In-hospital mortality | 1 (0.04%) | 1 (0.07%) | 0.7156 |

BMI body mass index, ASA American Society of Anesthesiologists
These findings correspond well with the literature and thus confirm the validity of our data. We also found that an ASA score higher than 2 was a risk factor that has never been reported by other studies.

In a rat colonic anastomosis model, flurbiprofen-treated rats had higher collagen levels than those of the control or prostaglandin E2 group, suggesting that inhibition of prostaglandin synthesis by administration of flurbiprofen may improve healing in the colon (Brennan et al. 1984). Similarly, in a newly published animal study, the author did not find evidence that diclofenac or ketorolac increases the leakage risk of colocolic anastomoses (Ghiselli et al. 2020). These results may explain the present study finding that short-term use of flurbiprofen does not seem to harm the healing of anastomoses. In our study, intraoperative transfusion was associated with an odds ratio of 2.24 for anastomotic leakage (Table 5). This result is expected, since intraoperative transfusion is a surrogate marker for a difficult procedure, a suboptimal surgical technique, or perhaps an insufficient anastomotic perfusion caused by anemia or hypotension. An ASA score higher than 2 was also identified as a risk factor, and we could not rule out other indirect factors that might be affected.

**Conclusion**

Postoperative short-term use of flurbiprofen did not increase the risk of anastomotic leakage in gastrointestinal anastomoses. However, a well-designed randomized clinical trial is warranted to verify the results of this observational study.

**Acknowledgements**

The authors wish to thank Chong Lei and Chen Li for participating in protocol discussion.

**Authors’ contributions**

Dr. Hailong Dong, Qingchuan Zhao, and Huang Nie conceptualized and designed the study. Huang Nie and Yiming Hao drafted the manuscript. Xiangying Feng, Lina Ma, Yumei Ma, and Zhen Zhang performed data collection. Xi’an Han and Jianzhong Zhang performed database maintenance. Xi’an Han performed data analysis. All authors interpreted the data. The author(s) read and approved the final manuscript.

**Funding**

This work was supported by the Discipline Promotion Plan of Xijing Hospital (XJZY18MDT08) and the Research and Development Project of Shaanxi Province (2020SF-295).

**Availability of data and materials**

The datasets generated during and/or analyzed during the current study are not publicly available due to statutory provisions regarding data and privacy protection.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by KY20202116-C-1 from Approval Form IEC of our hospital. The need for written informed consent was waived, because of the study’s retrospective nature.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Anesthesiology, Xijing Hospital, Air Force Medical University, Xi’an, China. 2. Department of Gastrointestinal Surgery, Xijing Hospital, Air Force Medical University, Xi’an, China. 3. The Unimed Scientific, Inc., Wu Xi, China.

Received: 15 December 2021   Accepted: 23 June 2022
Published online: 19 August 2022
References
Agha R, Abdall-Razak A, Crossley E, Dowlat N, Iosifidis C, Mathew G. STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156–65.
Alves A, Panis Y, Trancart D, Regimbeau JM, Pocard M, Valleur P. Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients. World J Surg. 2002;26:499–502.
Brennan SS, Foster ME, Morgan A, Leaper DJ. Prostaglandins in colonic anastomotic healing. Dis Colon Rectum. 1984;27:223–5.
Choi HK, Law WL, Ho JW. Leakage after resection and intraperitoneal anastomosis for colorectal malignancy: analysis of risk factors. Dis Colon Rectum. 2006;49:1719–25.
Ghiselli R, Lucarini G, Ortenzi M, Salvolini E, Saccomanno S, Orlando F, et al. Anastomotic healing in a rat model of peritonitis after non-steroidal anti-inflammatory drug administration. Eur J Histochem. 2020;64(1):3085.
Golub R, Golub RW, Caunitz Jr, Stein HD. A multivariate analysis of factors contributing to leakage of intestinal anastomoses. J Am Coll Surg. 1997;184:364–72.
Gorissen KJ, Benning D, Bergmann T, Snoeijis MG, Sosef MN, Hulsewe KW, et al. Risk of anastomotic leakage with non-steroidal anti-inflammatory drug preparations in colorectal surgery. Br J Surg. 2009;97:21–7.
Guennaga KK, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. Cochrane Database Syst Rev. 2009(1).CD001544. https://doi.org/10.1002/14651858.CD001544.pub3.
Haga Y, Wada Y, Takeuchi H, Ikejiri K, Ikenaga M. Prediction of anastomotic leakage and its prognosis in digestive surgery. World J Surg. 2011;35:716–22.
Inokuchi M, Otsuki S, Fujimori Y, Sato Y, Nakagawa M, Kojima K. Systematic review of anastomotic complications of esophagojejunostomy after laparoscopic total gastrectomy. World J Gastroenterol. 2015;21:9656–65.
Iversen LH, Bulow S, Christensen IJ, Laurberg S, Harling H. Postoperative medical complications are the main cause of early death after emergency surgery for colonic cancer. Br J Surg. 2008;95:1012–9.
Jamjittrong S, Matsuda A, Matsumoto S, Kamanvarapinta T, Sakurazawa N, Kawano Y, et al. Postoperative non-steroidal anti-inflammatory drugs and anastomotic leakage after gastrointestinal anastomoses: Systematic review and meta-analysis. Ann Gastroenterol Surg. 2020;4:64–75.
Klein M, Andersen LP, Harvald T, Rosenberg J, Goguen Jr. Increased risk of anastomotic leakage with dicolfenac treatment after laparoscopic colorectal surgery. Dig Surg. 2009;26:27–30.
Klein M, Goguen Jr, Rosenberg J. Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data. BMJ. 2012;345:e6166.
Kulu V, Ulfich A, Bruckner T, Contin P, Welsch T, Rahbani NN, et al. Validation of the International Study Group of Rectal Cancer definition and severity grading of anastomotic leakage. Surgery. 2013;153:753–61.
Kverneng Hultberg D, Angetepe E, Lydstrup ML, Rutegård J, Matthiessen P, Rutevgård M. Non-steroidal anti-inflammatory drugs and the risk of anastomotic leakage after anterior resection for rectal cancer. Eur J Surg Oncol. 2017;43:1908–14.
Lipska MA, Bissett IP, Parry BR, Merrie AE. Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk. ANZ J Surg. 2006;76:579–85.
Makela JT, Kviniemi H, Laitinen S. Risk factors for anastomotic leakage after left-sided colorectal resection with rectal anastomosis. Dis Colon Rectum. 2003;46:653–60.
Matthiessen P, Hallbäck O, Rutevgård J, Simert G, Sjödahl R. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg. 2007;246:207–14.
McDaid C, Maund E, Rice S, Wright K, Jenkins B, Woolcott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess. 2010;14:1–153 iii–iv.
Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg 2014;101:1209–29.
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873–90.
Nishina K, Mikawa K, Shiga M, Takao Y, Maekawa N, Obara H. Diclofenac and flurbiprofen with or without clonidine for postoperative analgesia in children undergoing elective ophthalmological surgery. Paediatr Anaesth. 2000;10:645–51.
Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, et al. Guideline for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Clin Nutr. 2012;31:816–17.
Saleh F, Jackson TD, Ambrosoli L, Granasegaram JJ, Kwong J, Querecy F, et al. Perioperative nonselective non-steroidal anti-inflammatory drugs are not associated with anastomotic leakage after colorectal surgery. J Gastrointest Surg. 2014;18:1398–404.
Sultan A, McQuay HJ, Moore RA, Derry S. Single dose oral flurbiprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;2009:CD007358.
Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500–24.
Zhang Z, Zhao H, Wang C, Han F, Wang G. Lack of preemptive analgesia by intravenous flurbiprofen in thyroid gland surgery: a randomized, double-blind and placebo-controlled clinical trial. Int J Med Sci. 2011;8:433–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.